Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease

Autoimmunity Reviews

Volumn 13, Issue 8, 2014, Pages 822-830

  Olivieri, Ignazio ^a   Cantini, Fabrizio ^b   Castiglione, Fabiana ^c   Felice, Carla ^d   Gionchetti, Paolo ^e   Orlando, Ambrogio ^f   Salvarani, Carlo ^g   Scarpa, Raffaele ^c   Vecchi, Maurizio ^h   Armuzzi, Alessandro ^d  

^a San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera   (Italy)

^b MISERICORDIA E DOLCE HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

^g S MARIA NUOVA HOSPITAL   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Crohn's disease; Inflammatory bowel disease; Integrated management; Spondyloarthritis; Therapeutic algorithm; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CELECOXIB; ETANERCEPT; ETORICOXIB; HLA B27 ANTIGEN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; ARTHRALGIA; BACKACHE; CLINICAL EXAMINATION; CROHN DISEASE; DACTYLITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FEVER; GASTROENTEROLOGIST; HUMAN; INFLAMMATORY BOWEL DISEASE; IRIDOCYCLITIS; JOINT RADIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; POLYARTHRITIS; PRACTICE GUIDELINE; PREVALENCE; PSORIATIC ARTHRITIS; RECTUM HEMORRHAGE; REVIEW; RHEUMATOLOGY; SPONDYLARTHRITIS; ULCERATIVE COLITIS; WEIGHT REDUCTION;

CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; INTEGRATED MANAGEMENT; SPONDYLOARTHRITIS; THERAPEUTIC ALGORITHM; ULCERATIVE COLITIS;

ALGORITHMS; HUMANS; INFLAMMATORY BOWEL DISEASES; JOINTS; REMISSION INDUCTION; SPONDYLARTHRITIS;

EID: 84902138014     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.04.003     Document Type: Review

References (73)

1. Turkcapar N., Toruner M., Soykan I., Aydintug O.T., Cetinkaya H., Duzgun N., et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006, 26(7):663-668.
2. Salvarani C., Vlachonikolis I.G., van der Heijde D.M., Fornaciari G., Macchioni P., Beltrami M., et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001, 36(12):1307-1313.
3. Salvarani C., Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009, 15(20):2449-2455.
4. Atzeni F., Defendenti C., Ditto M.C., Batticciotto A., Ventura D., Antivalle M., et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev Jan 2014, 13(1):20-23.
5. Peluso R., Di Minno M.N., Iervolino S., Manguso F., Tramontano G., Ambrosino P., et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013, 2013:631408.
6. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34(10):1218-1227.
7. Scarpa R., del Puente A., D'Arienzo A., di Girolamo C., della Valle G., Panarese A., et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992, 19(3):373-377.
8. de Vlam K., Mielants H., Cuvelier C., De Keyser F., Veys E.M., De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000, 27(12):2860-2865.
9. Wordsworth P. Arthritis and inflammatory bowel disease. Curr Rheumatol Rep 2000, 2(2):87-88.
10. Palm O., Moum B., Ongre A., Gran J.T. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002, 29(3):511-515.
11. Steer S., Jones H., Hibbert J., Kondeatis E., Vaughan R., Sanderson J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003, 30(3):518-522.
12. Van Assche G., Dignass A., Bokemeyer B., Danese S., Gionchetti P., Moser G., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013, 7(1):1-33.
13. Rodriguez-Reyna T.S., Martinez-Reyes C., Yamamoto-Furusho J.K. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol 2009, 15(44):5517-5524.
14. Palm O., Moum B., Jahnsen J., Gran J.T. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001, 40(11):1256-1261.
15. Orchard T.R., Wordsworth B.P., Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42(3):387-391.
16. Yuksel I., Ataseven H., Basar O., Koklu S., Ertugrul I., Ulker A., et al. Peripheral arthritis in the course of inflammatory bowel diseases. Dig Dis Sci 2011, 56(1):183-187.
17. Smale S., Natt R.S., Orchard T.R., Russell A.S., Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001, 44(12):2728-2736.
18. Veloso F.T., Carvalho J., Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996, 23(1):29-34.
19. Manguso F., Sanges M., Staiano T., Gargiulo S., Nastro P., Gargano D., et al. Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 2004, 99(2):327-334.
20. Manguso F., Staiano T., Astarita C., Scarpa R., Peluso R., Gargano D., et al. Consecutive occurrence of rhinoconjunctivitis, seronegative spondyloarthritis and pyoderma gangrenosum in a patient with ulcerative colitis. Int J Colorectal Dis 2005, 20(1):79-80.
21. Rispo A., Scarpa R., Di Girolamo E., Cozzolino A., Lembo G., Atteno M., et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand J Rheumatol 2005, 34(5):387-391.
22. Vavricka S.R., Brun L., Ballabeni P., Pittet V., Prinz Vavricka B.M., Zeitz J., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011, 106(1):110-119.
23. Queiro R., Maiz O., Intxausti J., de Dios J.R., Belzunegui J., Gonzalez C., et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol 2000, 19(6):445-449.
24. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41(1):58-67.
25. Brewerton D.A., Hart F.D., Nicholls A., Caffrey M., James D.C., Sturrock R.D. Ankylosing spondylitis and HL-A 27. Lancet 1973, 1(7809):904-907.
26. Khan M.A. Update on spondyloarthropathies. Ann Intern Med 2002, 136(12):896-907.
27. Rudwaleit M., van der Heijde D., Landewe R., Listing J., Akkoc N., Brandt J., et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68(6):777-783.
28. Rudwaleit M., van der Heijde D., Landewe R., Akkoc N., Brandt J., Chou C.T., et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70(1):25-31.
29. Wright V., Watkinson G. The arthritis of ulcerative colitis. Br Med J 1965, 2(5463):670-675.
30. Rothfuss K.S., Stange E.F., Herrlinger K.R. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006, 12(30):4819-4831.
31. Gravallese E.M., Kantrowitz F.G. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988, 83(7):703-709.
32. De Vos M. Review article: joint involvement in inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl. 4):36-42.
33. Mielants H., Veys E.M., Goethals K., Van Der Straeten C., Ackerman C. Destructive lesions of small joints in seronegative spondylarthropathies: relation to gut inflammation. Clin Exp Rheumatol 1990, 8(1):23-27.
34. Mallas E.G., Mackintosh P., Asquith P., Cooke W.T. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut 1976, 17(11):906-910.
35. Oostveen J., Prevo R., den Boer J., van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 1999, 26(9):1953-1958.
36. Mera-Varela A., Ferreiro-Iglesias A., Perez-Pampin E., Porto-Silva M., Gomez-Reino J.J., Gonzalez A. Ultrasonographic assessment of enthesitis in HLA-B27 positive patients with rheumatoid arthritis, a matched case-only study. PLoS One 2013, 8(3):e58616.
37. Laass M.W., Roggenbuck D., Conrad K. Diagnosis and classification of Crohn's disease. Autoimmun Rev April-May 2014, 13(4-5):467-471.
38. Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4(1):7-27.
39. Conrad K., Roggenbuck D., Laass M.W. Diagnosis and classification of ulcerative colitis. Autoimmun Rev April-May 2014, 13(4-5):463-466.
40. Dignass A., Eliakim R., Magro F., Maaser C., Chowers Y., Geboes K., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012, 6(10):965-990.
41. Cassinotti A., Sarzi-Puttini P., Fichera M., Shoenfeld Y., de Franchis R., Ardizzone S. Immunity, autoimmunity and inflammatory bowel disease. Autoimmun Rev Jan 2014, 13(1):1-2.
42. Monteleone G., Caruso R., Pallone F. Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmun Rev Jan 2014, 13(1):11-14.
43. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev Jan 2014, 13(1):3-10.
44. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4(1):28-62.
45. Orlando A., Armuzzi A., Papi C., Annese V., Ardizzone S., Biancone L., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011, 43(1):1-20.
46. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.F., Allez M., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012, 6(10):991-1030.
47. Braun J., van den Berg R., Baraliakos X., Boehm H., Burgos-Vargas R., Collantes-Estevez E., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70(6):896-904.
48. van der Heijde D., Sieper J., Maksymowych W.P., Dougados M., Burgos-Vargas R., Landewe R., et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70(6):905-908.
49. Gossec L., Smolen J.S., Gaujoux-Viala C., Ash Z., Marzo-Ortega H., van der Heijde D., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71(1):4-12.
50. Ritchlin C.T., Kavanaugh A., Gladman D.D., Mease P.J., Helliwell P., Boehncke W.H., et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68(9):1387-1394.
51. Harrell L.E., Hanauer S.B. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am 2004, 33(2):303-317. [ix-x].
52. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121(5):1088-1094.
53. Haraoui B., Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2009, 39(3):176-181.
54. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev Jan 2014, 13(1):24-30.
55. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362(15):1383-1395.
56. Javaid M.K., McCrudden P.R., Taylor P., Petley G.W., Stroud M., Fine D.R., et al. Comparison of calcaneal ultrasound and DXA to assess the risk of corticosteroid-induced osteoporosis: a cross-sectional study. Osteoporos Int 2001, 12(9):788-793.
57. Grossman J.M., Gordon R., Ranganath V.K., Deal C., Caplan L., Chen W., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010, 62(11):1515-1526.
58. De Cruz P., Kamm M.A., Hamilton A.L., et al. Adalimumab prevents post-operative Crohn's disease recurrence, and is superior to thiopurines: early results from the POCER study [abstract]. Gastroenterology 2012, 142(5):S212.
59. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136(2). [441-50 e1; quiz 716].
60. Colombel J.F., Schwartz D.A., Sandborn W.J., Kamm M.A., D'Haens G., Rutgeerts P., et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009, 58(7):940-948.
61. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350(9):876-885.
62. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340(18):1398-1405.
63. Marshall J.K., Thabane M., Steinhart A.H., Newman J.R., Anand A., Irvine E.J. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, (1):CD004115.
64. Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Miglioli M., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998, 41(1):93-97.
65. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 2:CD000544.
66. Marshall J.K., Irvine E.J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995, 9(3):293-300.
67. Velayos F.S., Loftus E.V., Jess T., Harmsen W.S., Bida J., Zinsmeister A.R., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006, 130(7):1941-1949.
68. Monterubbianesi R., Aratari A., Armuzzi A., Daperno M., Biancone L., Cappello M., et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis Jan 25 2014, [pii: S1873-9946(14)00010-5, Epub ahead of print]. 10.1016/j.crohns.2014.01.006.
69. Sandborn W.J., Stenson W.F., Brynskov J., Lorenz R.G., Steidle G.M., Robbins J.L., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006, 4(2):203-211.
70. El Miedany Y., Youssef S., Ahmed I., El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006, 101(2):311-317.
71. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142(1). [63-70 e5; quiz e31].
72. Truelove S.C., Watkinson G., Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962, 2(5321):1708-1711.
73. Misiewicz J.J., Lennard-Jones J.E., Connell A.M., Baron J.H., Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965, 285:185-188.